Shize Biotech: Completed 500 million yuan C/C+ round financing, marking six consecutive years of market-based financing

2026-04-02 04:21:56

Abstract generation in progress

On April 2, Shize Biotechnology announced that the company has continuously completed five rounds of 500 million yuan C/C+ market-oriented fundraising, completing market-oriented financing for six consecutive years. Led by the China Guofeng Investment Fund and the Suzhou Industrial Investment Social Security Fund, with co-investment from Yuyao Gongtou, Bank of China Capital, Shanghai Minjin Investment, Shanghai Pudong Haitong Fund (Haitong leading zone mother fund), Huajin Investment (under Zhuhai Technology Industry Group), and Jiaxing Innot, and continued additional investment from existing shareholders including Fengrui Capital, Suchuang Venture Angel Mother Fund, Xixi Capital, Qisheng Capital, and others.

This financing will be used to further support the advancement of multiple “China’s first release” or “the world’s first” allogeneic universal iPSC-derived cell new drugs independently developed by Shize Biotechnology into key confirmatory clinical stages, to enhance the company’s “spot-available” neural cell new drug large-scale and standardized production capabilities as well as its quality management and control system, and to provide assurance for the accessibility of commercial applications of Shize Biotechnology’s universal cell new drugs.

(Shize Biotechnology announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.